American Society of Hirudotherapy

Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention

Review published in Progress in cardiovascular diseases (1997)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsLefkovits J · Progress in cardiovascular diseases, 1997

Abstract

A large number of drug trials for prevention of restenosis have been conducted with many showing little or conflicting benefit. Antiplatelets such as aspirin, ticlopidine and thromboxane A2 receptor inhibitors have not shown a clear benefit. Similarly, antithrombotics, either acting indirectly such as heparin, or as direct thrombin inhibitors such as hirudin and hirulog, do not prevent restenosis. Trials with ACE inhibitors, HMG-CoA reductase inhibitors and fish-oil supplements have yielded inconclusive results. The antiproliferatives, angiopeptin, trapidil and tranilast have shown some benefit in small-scale studies. Other drug classes of potential benefit include the glycoprotein IIb/IIIa receptor antagonists, inhibitors of the early coagulation cascade, calcium channel blockers and nitric oxide donors. Drug research into restenosis prevention has been hampered by problems with the definition of restenosis and the applicability in humans of animal models. Although no single drug has conclusively proven effective yet, the promise of a number of agents, together with other nonpharmacological strategies will likely result in further reductions in the incidence of restenosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAbciximabAngioplasty, Balloon, CoronaryAngiotensin-Converting Enzyme InhibitorsAnimalsAntibodies, MonoclonalAnticoagulantsCardiovascular AgentsConstriction, PathologicCoronary AngiographyCoronary DiseaseCoronary VesselsDisease Models, Animal

Summary

A large number of drug trials for prevention of restenosis have been conducted with many showing little or conflicting benefit.

Why This Matters for Hirudotherapy

This review summarizes drug trials for the prevention of restenosis, noting that many have shown little or conflicting benefit. The abstract states that direct thrombin inhibitors such as hirudin and hirulog 'do not prevent restenosis,' alongside similar negative findings for antiplatelets and inconclusive results for ACE inhibitors and other agents. The abstract characterizes hirudin only as a direct thrombin inhibitor and does not mention leeches, leech saliva, or hirudotherapy. The article offers no information connecting hirudin to leeches or to ASH's domain of live leech therapy; it merely lists hirudin among drugs that failed to prevent restenosis.

Citation

Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention

Lefkovits J · Progress in cardiovascular diseases, 1997

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.